摘要
糖尿病治疗药物的开发是当前生物医药产业竞争最为激烈的领域之一,而诺和诺德与赛诺菲安万特两家企业堪称是国际市场竞争中的佼佼者,其发展模式和研发策略具有较强的代表性。本文对Thomson Innovation(TI)专利数据库收录的全球范围内申请的糖尿病新药专利进行了数据计量分析,给出了这两家企业在该领域专利的年度和地区分布以及重点技术领域、主要合作者、发明人等,通过探讨其发展方向和研发策略的得失,可以为我国生物医药企业的发展提供有益的参考和借鉴。
The development of antidiabetic drug is the most intense competition field of biopharmaceutical industries,and Novo Nordisk and Sanofi Aventis are the leader companies in the international market competition,so their development mode and development strategy have a strong representation. In this paper,the patents of antidiabetic drug from Thomson Innovation（ TI） patent database were collected and analyzed,and the annual and regional distribution,the main collaborators and the inventors of the patents in this field from Novo Nordisk and Sanofi Aventis were discussed. In addition,a useful reference for the development of Chinese biopharmaceutical enterprises can be provided through the discussion of their development directions and development strategies.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第5期494-498,共5页
Chinese Journal of New Drugs
基金
天津市科技发展战略研究计划项目(16ZLZDZF00450)
关键词
糖尿病
新药研究
专利
企业
对比分析
diabetes
new drug research
patent
enterprise
comparative analysis
